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Background: Hormone-refractory breast cancer metastatic to bone is a clinically challenging disease associated
with high morbidity, poor prognosis, and impaired quality of life owing to pain and skeletal-related events. In a
preclinical study using a mouse model of breast cancer and bone metastases, Ra-223 dichloride was incorporated
into bone matrix and inhibited proliferation of breast cancer cells and differentiation of osteoblasts and osteoclasts
(all P values < .001) in vitro. Ra-223 dichloride also induced double-strand DNA breaks in cancer cells in vivo.
Methods: The US Food and Drug Administration recently approved radium-223 (Ra-223) dichloride (Ra-223;
Xofigo injection) alpha-particle therapy for the treatment of symptomatic bone metastases in patients with
castration-resistant prostate cancer. On the basis of a strong preclinical rationale, we used Ra-223 dichloride to
treat bone metastases in a patient with breast cancer.
Results: A 44-year-old white woman with metastatic breast cancer who was estrogen receptor–positive,
BRCA1-negative, BRCA2-negative, PIK3CA mutation (p.His1047Arg) positive presented with diffuse bony metastases
and bone pain. She had hormone refractory and chemotherapy refractory breast cancer. After Ra-223 therapy
initiation her bone pain improved, with corresponding decrease in tumor markers and mixed response in 18F-FDG
PET/CT and 18F-NaF bone PET/CT. The patient derived clinical benefit from therapy.
Conclusion: We have shown that Ra-223 dichloride can be safely administered in a patient with hormone-refractory
bone metastasis from breast cancer at the US FDA–approved dose for prostate cancer. Furthermore, because the
treatment did not cause any drop in hematologic parameters, it has the potential to be combined with other
radiosensitizing therapies, which may include chemotherapy or targeted therapies. Given that Ra-223 dichloride is
already commercially available, this case report may help future patients and provide a rationale for initiating clinical
research in the use of Ra-223 dichloride to treat bone metastasis from breast cancer. A randomized clinical trial is
needed to provide evidence of efficacy, safety, and good outcomes.
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Hormone-refractory breast cancer metastatic to bone is a
clinically challenging disease associated with high morbid-
ity and poor prognosis. Common complications of bone
metastasis include skeletal-related events such as patho-
logic fractures, spinal cord compression, and nerve root
compression, as well as hypercalcemia of malignancy.
Moreover, bone pain impairs quality of life in patients with
bone metastases. Strategies to target bone metastases have
included bisphosphonate therapy (zoledronic acid), recep-
tor activator of nuclear factor kappa-B ligand (RANK-L)–
directed monoclonal antibody therapy (denosumab), and
palliative radiation in addition to systemic therapy [1-4]. A
recent major therapeutic advance was the US Food and
Drug Administration (FDA) approval of radium-223
(Ra-223) dichloride (Xofigo injection, Bayer HealthCare
Pharmaceuticals Inc) alpha particle therapy for the treat-
ment of symptomatic bone metastases in patients with
castration-resistant prostate cancer and no known visceral
metastatic disease [3,5-8]. Ra-223 is an isotope of radium
with an 11.4-day half-life, in contrast with the common
isotope Ra-226, discovered by the Curies, which has a
1601-year half-life.
In a preclinical study using a mouse model of breast
cancer and bone metastases, Ra-223 dichloride was in-
corporated into bone matrix and inhibited proliferation
of breast cancer cells and differentiation of osteoblasts
and osteoclasts (all P values < .001) in vitro. Ra-223
dichloride also induced double-strand DNA breaks in
cancer cells in vivo [9]. Moreover, Ra-223 dichloride ex-
tended survival duration when administered as a single
agent or in combination with zoledronic acid or che-
motherapy (doxorubicin) compared with control [9].
On the basis of this strong preclinical rationale, we used
Ra-223 dichloride to treat bone metastases in a patient
with breast cancer, and the patient derived clinical bene-
fit from the therapy. This case report may help future
patients and provide a rationale for initiating clinical re-
search in the use of Ra-223 dichloride to treat bone me-
tastases from breast cancer.
Clinical case report
A 44-year-old white woman with a history of hyperten-
sion, hypercholesterolemia, hypothyroidism, anxiety, and
renal stones presented in September 1992 with meta-
static breast cancer. At the time of diagnosis, her breast
tumor was estrogen receptor–positive, BRCA1-negative,
and BRCA2-negative, and the tumor had spread to 8 of
16 lymph nodes. She received frontline standard chemo-
therapy with doxorubicin, 5-fluorouracil, methotrexate,
and cyclophosphamide for 9 months, followed by oral
tamoxifen for 4 years and 6 months.
She was clinically stable until the summer of 2002,
when she started to complain of back pain. Magneticresonance imaging of the spine revealed osseous meta-
static disease in the spine involving the T1 vertebral
body. She was treated with directed radiation for 5 weeks
and then started taking the oral nonsteroidal aromatase
inhibitor letrozole, which she continued for 2 years,
along with zoledronic acid.
In April 2006, her tumor marker CA27-29 levels in-
creased to 76 U/mL. Magnetic resonance imaging and
computed tomography (CT) scans showed progressive
disease with multifocal osseous metastatic disease involv-
ing the spine. She ceased treatment with oral letrozole
and started taking fulvestrant, a selective estrogen recep-
tor downregulator, and she continued taking zoledronic
acid. Her CA27-29 levels initially decreased but then in-
creased again to 37 U/mL in November 2006. She con-
tinued with the anti-hormonal therapy (fulvestrant and
zoledronic acid), adding progesterone cream to her regi-
men in April and May 2007. In November 2007, her
CA27-29 levels decreased to 24 U/mL.
She continued with the same anti-hormonal therapy
from 2010 until 2013, when she was once again diag-
nosed with metastatic disease. In May 2013, she started
systemic therapy with the mammalian target of rapa-
mycin (mTOR) inhibitor everolimus in combination
with exemestane. She received only 3 cycles, with a
starting dose of 2.5 mg orally every day. The 6-week
therapy was complicated by shingles and abnormal liver
enzymes, and CA27-29 levels markedly increased to
705 U/mL. A CT scan on August 15, 2013, revealed no
evidence of visceral metastatic disease but showed stable
osseous metastatic disease in the spine. She reported
progressive bone pain affecting her back, shoulder, and
pelvic regions.
The patient was then referred to The University of
Texas MD Anderson Cancer Center Clinical Center for
Targeted Therapy to receive molecularly targeted therapy.
Pathologic review showed that the spinal tumor cells were
strongly positive for estrogen receptor (90%) and moder-
ately positive for progesterone receptor (15%). In addition,
HER-2/neu protein overexpression was equivocal (score
2+, 80%), and the Ki-67 proliferation index was positive in
less than 10% of tumor cells. Consistent with the path-
ology report, HER-2/neu gene amplification according to
fluorescence in situ hybridization was reported as equivo-
cal (score 1.83). This immune profile was consistent with
a breast tumor origin. A next generation sequencing–
based analysis for the detection of frequently reported
(hotspot) mutations in a total of 50 genes was performed
on DNA extracted from an archival sample from the
patient in the MD Anderson CLIA-certified molecular
diagnostics laboratory. PIK3CA mutation was detected in
codon 1047, exon 21 (CAT to CGT) of the PIK3CA gene,
which would change the encoded amino acid from
histidine to arginine (p.His1047Arg). Imaging studies
Figure 1 Graphical representation of tumor marker and alkaline
phosphatase over time. A: Tumor marker CA 27–29 levels after each
treatment with radium-223 (Ra-223) dichloride, B: Serial alkaline
phosphate (ALP) levels after each treatment with Ra-223 dichloride.
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her bones, and no visceral disease. Although several trials
were available for treatments targeting the PIK3CA path-
way, she was unfortunately not a candidate for the trials
because she had no RECIST measurable disease.
She was then referred to Biomedical Research Founda-
tion of Northwest Louisiana for evaluation and treat-
ment with bone-targeted therapy that included Ra-223.
Because of the lack of therapy options for hormone-
refractory bone metastasis from breast cancer, as well as
the strong preclinical data, Ra-223 dichloride therapy
was considered. Active osseous metastatic disease with-
out any visceral metastatic disease was confirmed by
18F-FDG positron emission tomography (PET)/CT and
18F-NaF bone PET/CT imaging prior to Ra-223 consi-
deration. The patient was counseled about the risks and
potential benefits of the therapy, the off-label nature of
the therapy, and expected adverse events, as well as
required precautions to be taken after Ra-223 is ad-
ministered. Laboratory evaluation was then performed
(complete blood count and chemistry profile) to ensure
that the patient was eligible for Ra-223 dichloride ther-
apy. After the patient provided informed consent for the
off-label use of Ra-223, she was treated with Ra-223
dichloride at a dose of 50 KBq/kg (or 1.35 uCi/kg) every
4 weeks. A total of 6 treatments were planned, and at
the time this case report was written, she had completed
4 of the 6 planned treatments. Before each treatment, la-
boratory evaluation was performed to assess for adverse
events related to hematologic parameters and to mea-
sure markers (CA27-29 and serum alkaline phosphate).
After 2 treatments, 18F-FDG PET/CT and 18F-NaF bone
PET/CT imaging studies were performed to evaluate
disease status.
The patient reported significant improvement in her
pain soon after the first treatment and has reported incre-
mental and sustained improvement in her pain with sub-
sequent treatments. This was accompanied by laboratory
evidence of response: CA27-29 levels were 957.6 U/mL at
baseline prior to first treatment and have consistently de-
creased with each treatment, to 483.9 U/mL after 4 treat-
ments. Serum alkaline phosphate levels were 134 IU/L at
baseline prior to first treatment and have also consistently
decreased with each treatment, to 99 IU/L after 4 treat-
ments. Figure 1 shows a graphical representation of the
decreases in CA27-29 (A) and alkaline phosphate levels
(B). At the time of this report (after 4 treatments), she re-
ported being pain-free without any analgesics, with a very
good quality of life and without any restrictions in her
daily activities.
18F-FDG PET/CT and 18F-NaF bone PET/CT imaging at
baseline prior to the first treatment showed multifocal osse-
ous metastatic disease with intense uptake. Repeat qualita-
tive and quantitative 18F-FDG PET/CT and 18F-NaF bonePET/CT imaging after 2 treatments (but prior to the third
treatment) showed an overall mixed change in the lesions,
with improvement in some lesions but potential progres-
sion in others. The lesions were assessed for their uptake
of FDG and NaF (semiquantitatively, using the standar-
dized uptake value [SUV]) as well as for their density on
the CT portion of the study (Hounsfield units [HU]).
For the sake of this report, 2 index lesions were se-
lected for analysis on the 18F-FDG PET/CT (Figure 2)
and 18F-NaF bone PET/CT (Figure 3) imaging studies.
At baseline, the 18F-FDG PET/CT study showed a lesion
in the L-2 vertebral body with a maximum SUV of 9.8
and an average SUV of 6.1, and maximum HU of 573
and average HU of 398.9; as well as a lesion in the right
proximal femur with a maximum SUV of 12.3 and an
average SUV of 7.6, and maximum HU of 348 and aver-
age HU of 130.9. On the 18F-FDG PET/CT study per-
formed after 2 treatments, the lesion in the L-2 vertebral
body appeared less intense and more dense or sclerotic,
with a maximum SUV of 7.9 and an average SUV of 4.7,
and maximum HU of 636 and average HU of 489.8. This
indicates interval improvement. However, the lesion in
the right proximal femur appeared larger and more
A 
B 
Figure 2 Imaging study with 18F-FDG PET/CT. A: 18F-FDG PET/CT imaging studies at baseline, before administration of radium-223 (Ra-223)
dichloride, B: 8F-FDG PET/CT imaging studies after 2 treatments with Ra-223 dichloride but before the third treatment.
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SUV of 8.2, and maximum HU of 304 and average HU
of 95.1. This indicates potential interval worsening or
progression.
Similarly, at baseline, the 18F-NaF bone PET/CT study
showed a lesion in the left scapula with a maximum
SUV of 54.6 and an average SUV of 33.3, and maximum
HU of 687 and average HU of 179.6; as well as a lesion
in the right proximal femur with a maximum SUV of
31.3 and an average SUV of 17.7, and maximum HU of
431 and average HU of 152.3. On the 18F-NaF bone
PET/CT study performed after 2 treatments, the lesion
in the left scapula appeared less intense and more dense
or sclerotic, with a maximum SUV of 21.4 and an aver-
age SUV of 13.4, and maximum HU of 757 and average
HU of 234.4. This indicates interval improvement. How-
ever, the lesion in the right proximal femur appeared lar-
ger and more intense, with a maximum SUV of 52.6 and
an average SUV of 31.4, and maximum HU of 265 and
average HU of 125.7. This indicates potential interval
worsening or progression.Discussion
To the best of our knowledge, we have reported the first
clinical case of hormone-refractory bone metastases from
breast cancer responding to alpha-particle Ra-223 therapy
outside the context of a clinical trial, soon after US FDA
approval of Ra-223 dichloride for the treatment of bone
metastases from prostate cancer. After the submission of
this case study a phase IIa, nonrandomized study of
radium-223 dichloride in advanced breast cancer patients
with bone-dominant disease was also published [10].
Twenty-three advanced breast cancer patients with re-
lapsed breast cancer in the bone were administered
radium-223 (50 kBq/kg IV) every 4 weeks for 4 cycles. It
was demonstrated that Radium-223 was safe in breast
cancer in addition to clinically target areas of increased
bone metabolism [10].
Cancer-related mortality is often the result of metastatic
disease, especially metastases in the lungs, brain, liver, and
bone. For bone metastases, bisphosphonates and RANK-L
monoclonal antibody are the mainstay targeted therapies,
in addition to the systemic therapy armamentarium [4].
A 
B 
Figure 3 Imaging study with 18Na-F Bone PET/CT. A: 18NA-F bone PET/CT imaging studies at baseline, before administration of radium-223
(Ra-223) dichloride, B: 8NA-F bone PET/CT imaging studies after 2 treatments with Ra-223 dichloride but before the third treatment.
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apies such as samarium are toxic to bone marrow and
have limited effectiveness because they cannot be com-
bined with other systemic therapies.
Ongoing clinical trials of treatments involving radium
include expanded use of cabazitaxel for the treatment of
prostate cancer, Alpharadin for the treatment of bone-
dominant metastatic breast cancer no longer considered
suitable for hormone therapy (NCT01070485), and a
phase I dose escalation trial of monthly intravenous
Ra-223 dichloride for the treatment of osteosarcoma
(NCT01833520).
For the patient in the current case report, we observed
a positive treatment effect of Radium 223 in hormone-
refractory bone metastases from breast cancer. Close
follow-up with imaging and monitoring of serial tumor
markers is planned. Our initial assessment indicated a
very good clinical response, with a significant drop in
tumor and alkaline phosphatase marker levels. Imagingresults were more mixed, and further investigation is
needed to determine the potential for the flare
phenomenon and the most optimal imaging modality.
Conclusion
We have shown that Ra-223 dichloride can be adminis-
tered without toxicity in a patient with hormone-refractory
bone metastasis from breast cancer at the US FDA–
approved dose for prostate cancer. Furthermore, because
the treatment did not cause any drop in hematologic pa-
rameters, it has the potential to be combined with other
radiosensitizing therapies, which may include chemother-
apy or targeted therapies. Given that Ra-223 dichloride is
already available on the market, this case report may help
future patients and provide a rationale for initiating clinical
research in the use of Ra-223 dichloride to treat bone me-
tastasis from breast cancer. A randomized clinical trial is
needed to provide evidence of efficacy, safety, and good
outcomes.
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cancer is associated with high morbidity, poor
prognosis, and impaired quality of life owing to
pain and skeletal-related events.
 The US Food and Drug Administration recently
approved radium-223 (Ra-223) dichloride (Xofigo
injection, Bayer HealthCare Pharmaceuticals Inc)
alpha particle therapy for the treatment of
symptomatic bone metastases in patients with
castration-resistant prostate cancer.
 We used Ra-223 dichloride to successfully treat
hormone-refractory bone metastases in a patient
with breast cancer.
 Our initial assessment indicated a very good clinical
response, with a significant drop in tumor and bone
turnover marker levels; however, imaging results
were more mixed, and further investigation is
needed.
 Ra-223 dichloride can be safely administered in a
patient with hormone-refractory bone metastases
from breast cancer.
 A randomized clinical trial is needed to provide
evidence of efficacy, safety, and good outcomes.
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